Skip to main content
Premium Trial:

Request an Annual Quote

Agendia Files for IPO in Europe

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agendia has filed for an initial public offering to sell shares on the NYSE Euronext in Amsterdam.

The Dutch molecular diagnostics firm plans to sell up to 4,587,156 newly issued ordinary shares at a price of between €16.35 to €19.15 per share. At the mid-point of that range, it would raise around €81.4 million ($119 million), before an over-allotment option of up to 688,073 newly issued ordinary shares.

Agendia expects to begin trading on the NYSE Euronext in Amsterdam on June 21, under the symbol "AGDX".

The firm will use the proceeds partly to expand its sales and marketing efforts in the US. Agendia sells the MammaPrint breast cancer recurrence assay, the first in vitro diagnostic multivariate index assay device approved by the US Food and Drug Administration in early 2007.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.